Merck’s latest investigational drug, calderasib, is not merely another entry into the burgeoning field of KRAS G12C inhibition; it represents…
Read More

Merck’s latest investigational drug, calderasib, is not merely another entry into the burgeoning field of KRAS G12C inhibition; it represents…
Read More
Merck has unveiled its investigational KRAS G12C inhibitor, calderasib, positioning it not merely as another potent molecule in a rapidly…
Read More